A study was conducted to demonstrate that MDM2 amplification levels could be associated with changes in these tumors’ metabolism, in which six patient-derived dedifferentiated liposarcoma models were put through a comprehensive metabolomic and lipidomic analysis to ascertain associations with MDM2 amplification and response to metabolic disorders [30]. This evidence concerns the gene MDM2 and liposarcoma.